Media Coverage

The Pittsburgh Technology Council celebrated the 25th annual Tech 50 Awards on Nov. 10, 2021 to honor the fastest growing and most innovative technology companies, service providers and CEOS in the Pittsburgh region.

Technology looked a lot different 25 years ago when the first Tech 50 Awards were presented by the Pittsburgh Technology Council. There was an internet (just barely), cell phones were big and clunky (but not…

EY announces the 27 women founders selected for the EY Entrepreneurial Winning Women™ North America Class of 2021. The program, now in its 14th year, identifies ambitious women entrepreneurs who are leading thriving organizations and provides them with…

Seven companies have been selected to be part of the inaugural cohort of AlphaLab Health.

We checked in with experts in the tech sector and, based on our own knowledge, came up with our picks for the top tech companies to watch in 2021.

A new drug developed by a Pittsburgh-based biotechnology company is showing promise in treating COVID-19. The Wolf Administration hosted a news conference Wednesday morning to announce the development of the new drug.

On Wednesday, the Wolf Administration plans to highlight what it calls in a news advisory a “promising new drug candidate to treat COVID-19.”

December 09, 2020
PROMISING NEW TREATMENT

CytoAgents, based in Pittsburgh, says it is beginning its Phase 1 clinical trial for a new drug showing promise in the treatment of COVID-19.

In a press conference Wednesday afternoon, the Department of Community and Economic Development introduced CytoAgents, a Ben Franklin Technology Partners company.

A North Shore biotech company is reporting encouraging early clinical results for a new COVID-19 treatment that targets the disease’s inflammatory process.

GP1681 “has the potential to be the next best practice in medicine in areas with significant unmet need,” CytoAgents CEO Teresa Whalen said.

CytoAgents CEO, Teresa Whalen, RPh spoke with Bill Flanagan at WPXI-TV about our lead drug candidate GP1681 entering clinical trials. She discussed how GP1681 is designed to calm the “cytokine storm,” a condition triggered by COVID-19, influenza, and other respiratory viruses. Often,…